Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Intervention Strategy for High-risk Hepatitis B Related Hepatocellular Carcinoma Based on Liquid Biopsy Screening Technique

NCT05256459 is registered in ClinicalTrials.gov with Zhang Dazhi,MD as lead sponsor.

NCT NCT05256459
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05256459 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Intervention Strategy for High-risk Hepatitis B Related Hepatocellular Carcinoma Based on Liquid Biopsy Screening Technique
Lead sponsor
Zhang Dazhi,MD
Phase
Observational
Overall status
Unknown status
Start date
May 10, 2022
Completion date
December 15, 2024
Enrollment
1,000 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

time